A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
Recruiting · NCT06791681 · Registry updated 2025-02-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Early phase 1 | 2025-02-11 | NCT06791681 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chunrui Li | 2 |
| Shenzhen Pregene Biopharma Co., Ltd. | 7 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Tongji Hospital, Tongji Medical College | Wuhan | China | 1 |